Bromocriptine

Medical uses

Bromocriptine is used to treat acromegaly and conditions associated with hyperprolactinemia like amenorrhea, infertility, hypogonadism, and prolactin-secreting adenomas. It is also used to prevent ovarian hyperstimulation syndrome and to treat Parkinson's disease.

Since the late 1980s it has been used, off-label, to reduce the symptoms of cocaine withdrawal but the evidence for this use is poor. Bromocriptine has been successfully used in cases of galactorrhea precipitated by dopamine antagonists like risperidone.

A quick-release formulation of bromocriptine, Cycloset, is also used to treat type 2 diabetes. When administered within 2 hours of awakening, it increases hypothalamic dopamine level. That results to a significant weight loss as well as decreases in blood glucose levels, hepatic glucose production, and insulin resistance. It therefore acts as an adjunct to diet and exercise to improve glycemic control and cardiovascular risk.

Side effects

Most frequent side effects are nausea, orthostatic hypotension, headaches, and vomiting through stimulation of the brainstem vomiting centre. Vasospasms with serious consequences such as myocardial infarction and stroke that have been reported in connection with the puerperium, appear to be extremely rare events. Peripheral vasospasm (of the fingers or toes) can cause Raynaud's phenomenon.

Bromocriptine use has been anecdotally associated with causing or worsening psychotic symptoms (its mechanism is in opposition of most antipsychotics, whose mechanisms generally block dopamine receptors). It should be understood, however, that the greater affinity bromocriptine and many similar antiparkinson's drugs have for the D2S receptor form (considered to be mostly present at inhibitory D2 autoreceptor locatations) relative to the D2L form, sufficiently low partial agonist activity (ie where a molecule binding to a receptor induces limited effects while preventing a stronger ligand like dopamine from binding), and, possibly, the functional selectivity of a particular drug may generate antidopaminergic effects that are more similar than oppositional in nature to antipsychotics.

Pulmonary fibrosis has been reported when bromocriptine was used in high doses for the treatment of Parkinson's disease.

Use to suppress milk production after childbirth was reviewed in 2014 and it was concluded that in this context a causal association with serious cardiovascular, neurological or psychiatric events could not be excluded with an overall incidence estimated to range between 0.005% and 0.04%. Additional safety precautions and stricter prescribing rules were suggested based on the data. It is a bile salt export pump inhibitor.

After long-term use of dopamine agonists, a withdrawal syndrome may occur during dose reduction or discontinuation with the following possible side effects: anxiety, panic attacks, dysphoria, depression, agitation, irritability, suicidal ideation, fatigue, orthostatic hypotension, nausea, vomiting, diaphoresis, generalized pain, and drug cravings. For some individuals, these withdrawal symptoms are short-lived and they make a full recovery, for others a protracted withdrawal syndrome may occur with withdrawal symptoms persisting for months or years.

Pharmacology

Pharmacodynamics

Bromocriptine is a partial agonist of the dopamine D2 receptor. It also interacts with other dopamine receptors and with various serotonin and adrenergic receptors. Bromocriptine has additionally been found to inhibit the release of glutamate by reversing the glutamate transporter 1 (GLT-1; EAAT2).

Despite acting as a serotonin 5-HT2A receptor agonist, bromocriptine is described as non-hallucinogenic.

As a silent antagonist of the serotonin 5-HT2B receptor, bromocriptine has been said not to pose a risk of cardiac valvulopathy. This is in contrast to other ergolines acting instead as 5-HT2B receptor agonists such as cabergoline and pergolide but is similar to lisuride which likewise acts as a 5-HT2B receptor antagonist. However, in other research, bromocriptine has subsequently been found to be a partial agonist of the serotonin 5-HT2B receptor and has been associated with cardiac valvulopathy and related complications. In any case, bromocriptine seems to have lower risk than certain other drugs.

Chemistry

Like all ergopeptides, bromocriptine is a cyclol; two peptide groups of its tripeptide moiety are crosslinked, forming the N-C(OH)

Bromocriptine is a semisynthetic derivative of a natural ergot alkaloid, ergocryptine (a derivative of lysergic acid), which is synthesized by bromination of ergocryptine using N-bromosuccinimide.

History

Bromocriptine was discovered by scientists at Sandoz in 1965 and was first published in 1968; it was first marketed under the brand name Parlodel.

A quick-release formulation of bromocriptine was approved by the FDA in 2009.

Society and culture

Brand names

As of July 2017, bromocriptine was sold under many brand names worldwide, including Abergin, Barlolin, Brameston, Brocriptin, Brom, Broma-Del, Bromergocryptine, Bromergon, Bromicon, Bromocorn, Bromocriptin, Bromocriptina, Bromocriptine, Bromocriptine mesilate, Bromocriptine mesylate, Bromocriptine methanesulfonate, Bromocriptini mesilas, Bromocriptinmesilat, Bromodel, Bromokriptin, Bromolac, Bromotine, Bromtine, Brotin, Butin, Corpadel, Cripsa, Criptine, Criten, Cycloset, Degala, Demil, Deparo, Deprolac, Diacriptin, Dopagon, Erenant, Grifocriptina, Gynodel, kirim, Kriptonal, Lactodel, Medocriptine, Melen, Padoparine, Palolactin, Parlodel, Pravidel, Proctinal, Ronalin, Semi-Brom, Serocriptin, Serocryptin, Suplac, Syntocriptine, Umprel, Unew, Updopa, Upnol B, and Volbro.

As of July 2017 it was also sold as a combination drug with metformin as Diacriptin-M, and as a veterinary drug under the brand Pseudogravin.

References

References

1. (May 2025). "Therapeutic Goods (Poisons Standard— June 2025) Instrument 2025".
2. (August 2022). "Bromocriptine therapy: Review of mechanism of action, safety and tolerability". Clin Exp Pharmacol Physiol.
3. (April 2011). "Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes". Diabetes Care.
4. (14 June 2024). "Bromocriptine".
5. (2006). "Analogue-based Drug Discovery". John Wiley & Sons.
6. (January 2012). "Bromocriptine mesylate tablets -- original uses". FDA.
7. (February 2017). "Diagnosis and Treatment of Pituitary Adenomas: A Review". JAMA.
8. (14 Apr 2021). "Dopamine agonists for preventing ovarian hyperstimulation syndrome". The Cochrane Database of Systematic Reviews.
9. (May 2015). "Dopamine agonists for the treatment of cocaine dependence". The Cochrane Database of Systematic Reviews.
10. (February 2017). "Bromocriptine mesylate tablet label". FDA.
11. (2013). "The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations". Endocrine Practice.
12. (October 2015). "Efficacy and Safety of Bromocriptine-QR in Type 2 Diabetes: A Systematic Review and Meta-Analysis". Hormone and Metabolic Research.
13. (July 2023). "Effect of bromocriptine on glycemic control, risk of cardiovascular diseases and weight in patients with type 2 diabetes: a systematic review". Diabetology & Metabolic Syndrome.
14. (April 2011). "Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes". Diabetes Care.
15. (1986). "The safety of bromocriptine in long-term use: a review of the literature". Current Medical Research and Opinion.
16. (1996). "Bromocriptine related atypical vascular accidents postpartum identified through medicolegal reviews". Medicine and Law.
17. (1995). "Bromocriptine and psychosis: a literature review". The Psychiatric Quarterly.
18. (December 2014). "The role of D2-autoreceptors in regulating dopamine neuron activity and transmission". Neuroscience.
19. (1990). "Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease". Clinical and Experimental Neurology.
20. (2018-09-17). "European Medicines Agency - News and Events - CMDh endorses restricted use of bromocriptine for stopping breast milk production".
21. (2014-08-25). "EMA rät vom Abstillmittel Bromocriptin ab".
22. (January 2016). "Flagging Drugs That Inhibit the Bile Salt Export Pump". Molecular Pharmaceutics.
23. (August 2013). "Dopamine agonist withdrawal syndrome: implications for patient care". Drugs & Aging.
24. (June 2010). "The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells". Biochemical Pharmacology.
25. (September 2010). "Bromocriptine, an ergot alkaloid, inhibits excitatory amino acid release mediated by glutamate transporter reversal". European Journal of Pharmacology.
26. (January 2024). "Psychedelics: preclinical insights provide directions for future research". Neuropsychopharmacology.
27. (2014). "Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy". J Pharmacol Toxicol Methods.
28. (June 2014). "AACE/ACE Disease State Clinical Review: Dopamine Agonists for Hyperprolactinemia and the Risk of Cardiac Valve Disease". Endocr Pract.
29. (July 2012). "Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment". Eur J Endocrinol.
30. (March 2012). "A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas". Pituitary.
31. (February 2009). "Bromocriptine use and the risk of valvular heart disease". Mov Disord.
32. (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes". J Pharmacol Exp Ther.
33. (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor". J Pharmacol Exp Ther.
34. (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes". J Pharmacol Exp Ther.
35. "PDSP Database - UNC".
36. "2-Bromo-alpha-ergocryptine".
37. "Verfahren zur Herstellung einer neuen heterocyclischen Verbindung [Process for the preparation of a new heterocyclic compound]".
38. (2005). "Drug Discovery: A History". John Wiley & Sons.
39. (2014). "Fungal Metabolites as Pharmaceuticals". Australian Journal of Chemistry.
40. (December 2010). "Bromocriptine: old drug, new formulation and new indication". Diabetes, Obesity & Metabolism.
41. "Bromocriptine international brand names". Drugs.com.